The Application of Nanoparticles Targeting Cancer-Associated Fibroblasts

References

• Quail DF, Joyce JA. Microenvironmental regulation of tumor progression and metastasis. Nat Med. 2013;19(11):1423–1437. doi:10.1038/nm.3394
   PubMed Web of Science ®Google Scholar
• Hinshaw DC, Shevde LA. The tumor microenvironment innately modulates cancer progression. Cancer Res. 2019;79(18):4557–4566. doi:10.1158/0008-5472.CAN-18-3962
   PubMed Web of Science ®Google Scholar
• Chen F, Zhuang X, Lin L, et al. New horizons in tumor microenvironment biology: challenges and opportunities. BMC Med. 2015;13:45. doi:10.1186/s12916-015-0278-7
   PubMed Web of Science ®Google Scholar
• Baldominos P, Barbera-Mourelle A, Barreiro O, et al. Quiescent cancer cells resist T cell attack by forming an immunosuppressive niche. Cell. 2022;185(10):1694–1708.e19. doi:10.1016/j.cell.2022.03.033
   PubMed Web of Science ®Google Scholar
• Erin N, Grahovac J, Brozovic A, et al. Tumor microenvironment and epithelial mesenchymal transition as targets to overcome tumor multidrug resistance. Drug Resist Updat. 2020;53:100715. doi:10.1016/j.drup.2020.100715
   PubMed Web of Science ®Google Scholar
• Kim HJ, Ji YR, Lee YM. Crosstalk between angiogenesis and immune regulation in the tumor microenvironment. Arch Pharm Res. 2022;45(6):401–416. doi:10.1007/s12272-022-01389-z
   PubMed Web of Science ®Google Scholar
• Chen X, Song E. Turning foes to friends: targeting cancer-associated fibroblasts. Nat Rev Drug Discov. 2019;18(2):99–115. doi:10.1038/s41573-018-0004-1
   PubMed Web of Science ®Google Scholar
• Kalluri R. The biology and function of fibroblasts in cancer. Nat Rev Cancer. 2016;16(9):582–598. doi:10.1038/nrc.2016.73
   PubMed Web of Science ®Google Scholar
• Rimal R, Desai P, Daware R, et al. Cancer-associated fibroblasts: origin, function, imaging, and therapeutic targeting. Adv Drug Deliv Rev. 2022;189:114504. doi:10.1016/j.addr.2022.114504
   PubMed Web of Science ®Google Scholar
• Bainbridge P. Wound healing and the role of fibroblasts. J Wound Care. 2013;22(8):407–412. doi:10.12968/jowc.2013.22.8.407
   PubMed Web of Science ®Google Scholar
• Dvorak HF, Underhill LH, Dvorak HF. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med. 1986;315(26):1650–1659. doi:10.1056/NEJM198612253152606
   PubMed Web of Science ®Google Scholar
• Peng D, Fu M, Wang M, et al. Targeting TGF-β signal transduction for fibrosis and cancer therapy. Mol Cancer. 2022;21(1):104. doi:10.1186/s12943-022-01569-x
   PubMed Web of Science ®Google Scholar
• Mizutani Y, Kobayashi H, Iida T, et al. Meflin-positive cancer-associated fibroblasts inhibit pancreatic carcinogenesis. Cancer Res. 2019;79(20):5367–5381. doi:10.1158/0008-5472.CAN-19-0454
   PubMed Web of Science ®Google Scholar
• Biffi G, Tuveson DA. Diversity and biology of cancer-associated fibroblasts. Physiol Rev. 2021;101(1):147–176. doi:10.1152/physrev.00048.2019
   PubMed Web of Science ®Google Scholar
• Chen Y, McAndrews KM, Kalluri R. Clinical and therapeutic relevance of cancer-associated fibroblasts. Nat Rev Clin Oncol. 2021;18(12):792–804. doi:10.1038/s41571-021-00546-5
   PubMed Web of Science ®Google Scholar
• Bockamp E, Rosigkeit S, Siegl D, et al. Nano-enhanced cancer immunotherapy: immunology encounters nanotechnology. Cells. 2020;9(9):2102. doi:10.3390/cells9092102
   PubMed Web of Science ®Google Scholar
• Pérez-Herrero E, Fernández-Medarde A. Advanced targeted therapies in cancer: drug nanocarriers, the future of chemotherapy. Eur J Pharm Biopharm. 2015;93:52–79. doi:10.1016/j.ejpb.2015.03.018
   PubMed Web of Science ®Google Scholar
• Liu M, Song W, Huang L. Drug delivery systems targeting tumor-associated fibroblasts for cancer immunotherapy. Cancer Lett. 2019;448:31–39. doi:10.1016/j.canlet.2019.01.032
   PubMed Web of Science ®Google Scholar
• Farokhzad OC, Langer R. Impact of nanotechnology on drug delivery. ACS Nano. 2009;3(1):16–20. doi:10.1021/nn900002m
   PubMed Web of Science ®Google Scholar
• Lang J, Zhao X, Qi Y, et al. Reshaping prostate tumor microenvironment to suppress metastasis via cancer-associated fibroblast inactivation with peptide-assembly-based nanosystem. ACS Nano. 2019;13(11):12357–12371. doi:10.1021/acsnano.9b04857
   PubMed Web of Science ®Google Scholar
• Zhen Z, Tang W, Wang M, et al. Protein nanocage mediated fibroblast-activation protein targeted photoimmunotherapy to enhance cytotoxic T cell infiltration and tumor control. Nano Lett. 2017;17(2):862–869. doi:10.1021/acs.nanolett.6b04150
   PubMed Web of Science ®Google Scholar
• Pitt JM, Marabelle A, Eggermont A, et al. Targeting the tumor microenvironment: removing obstruction to anticancer immune responses and immunotherapy. Ann Oncol. 2016;27(8):1482–1492. doi:10.1093/annonc/mdw168
   PubMed Web of Science ®Google Scholar
• Hanahan D, Coussens LM. Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell. 2012;21(3):309–322. doi:10.1016/j.ccr.2012.02.022
   PubMed Web of Science ®Google Scholar
• Gajewski TF, Schreiber H, Fu YX. Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol. 2013;14(10):1014–1022. doi:10.1038/ni.2703
   PubMed Web of Science ®Google Scholar
• Coussens LM, Zitvogel L, Palucka AK. Neutralizing tumor-promoting chronic inflammation: a magic bullet? Science. 2013;339(6117):286–291. doi:10.1126/science.1232227
   PubMed Web of Science ®Google Scholar
• Zhang Y, Zhang Z. The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. Cell Mol Immunol. 2020;17(8):807–821. doi:10.1038/s41423-020-0488-6
   PubMed Web of Science ®Google Scholar
• Russell SJ, Peng KW, Bell JC. Oncolytic virotherapy. Nat Biotechnol. 2012;30(7):658–670. doi:10.1038/nbt.2287
   PubMed Web of Science ®Google Scholar
• van der Bruggen P, Traversari C, Chomez P, et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science. 1991;254(5038):1643–1647. doi:10.1126/science.1840703
   PubMed Web of Science ®Google Scholar
• Berraondo P, Sanmamed MF, Ochoa MC, et al. Cytokines in clinical cancer immunotherapy. Br J Cancer. 2019;120(1):6–15. doi:10.1038/s41416-018-0328-y
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Restifo NP. Adoptive cell transfer as personalized immunotherapy for human cancer. Science. 2015;348(6230):62–68. doi:10.1126/science.aaa4967
   PubMed Web of Science ®Google Scholar
• Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252–264. doi:10.1038/nrc3239
   PubMed Web of Science ®Google Scholar
• Peng S, Xiao F, Chen M, et al. Tumor-microenvironment-responsive nanomedicine for enhanced cancer immunotherapy. Adv Sci (Weinh). 2022;9(1):e2103836. doi:10.1002/advs.202103836
   PubMedGoogle Scholar
• D’Arcangelo E, Wu NC, Cadavid JL, et al. The life cycle of cancer-associated fibroblasts within the tumour stroma and its importance in disease outcome. Br J Cancer. 2020;122(7):931–942. doi:10.1038/s41416-019-0705-1
   PubMed Web of Science ®Google Scholar
• Räsänen K, Vaheri A. Activation of fibroblasts in cancer stroma. Exp Cell Res. 2010;316(17):2713–2722. doi:10.1016/j.yexcr.2010.04.032
   PubMed Web of Science ®Google Scholar
• Piersma B, Hayward MK, Weaver VM. Fibrosis and cancer: a strained relationship. Biochim Biophys Acta Rev Cancer. 2020;1873(2):188356. doi:10.1016/j.bbcan.2020.188356
   PubMed Web of Science ®Google Scholar
• Mao X, Xu J, Wang W, et al. Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: new findings and future perspectives. Mol Cancer. 2021;20(1):131. doi:10.1186/s12943-021-01428-1
   PubMed Web of Science ®Google Scholar
• Wan X, Guan S, Hou Y, et al. FOSL2 promotes VEGF-independent angiogenesis by transcriptionnally activating Wnt5a in breast cancer-associated fibroblasts. Theranostics. 2021;11(10):4975–4991. doi:10.7150/thno.55074
   PubMed Web of Science ®Google Scholar
• Li Z, Sun C, Qin Z. Metabolic reprogramming of cancer-associated fibroblasts and its effect on cancer cell reprogramming. Theranostics. 2021;11(17):8322–8336. doi:10.7150/thno.62378
   PubMed Web of Science ®Google Scholar
• Gong J, Lin Y, Zhang H, et al. Reprogramming of lipid metabolism in cancer-associated fibroblasts potentiates migration of colorectal cancer cells. Cell Death Dis. 2020;11(4):267. doi:10.1038/s41419-020-2434-z
   PubMed Web of Science ®Google Scholar
• Xi L, Peng M, Liu S, et al. Hypoxia-stimulated ATM activation regulates autophagy-associated exosome release from cancer-associated fibroblasts to promote cancer cell invasion. J Extracell Vesicles. 2021;10(11):e12146. doi:10.1002/jev2.12146
   PubMed Web of Science ®Google Scholar
• Li C, Teixeira AF, Zhu H-J, et al. Cancer associated-fibroblast-derived exosomes in cancer progression. Mol Cancer. 2021;20(1):154. doi:10.1186/s12943-021-01463-y
   PubMed Web of Science ®Google Scholar
• Nicolas AM, Pesic M, Engel E, et al. Inflammatory fibroblasts mediate resistance to neoadjuvant therapy in rectal cancer. Cancer Cell. 2022;40(2):168–184.e13. doi:10.1016/j.ccell.2022.01.004
   PubMed Web of Science ®Google Scholar
• Kieffer Y, Hocine HR, Gentric G, et al. Single-cell analysis reveals fibroblast clusters linked to immunotherapy resistance in cancer. Cancer Discov. 2020;10(9):1330–1351. doi:10.1158/2159-8290.CD-19-1384
   PubMed Web of Science ®Google Scholar
• Zhao P, Tian Y, Lu Y, et al. Biomimetic calcium carbonate nanoparticles delivered IL-12 mRNA for targeted glioblastoma sono-immunotherapy by ultrasound-induced necroptosis. J Nanobiotechnology. 2022;20(1):525. doi:10.1186/s12951-022-01731-z
   PubMed Web of Science ®Google Scholar
• Costa A, Kieffer Y, Scholer-Dahirel A, et al. Fibroblast heterogeneity and immunosuppressive environment in human breast cancer. Cancer Cell. 2018;33(3):463–479.e10. doi:10.1016/j.ccell.2018.01.011
   PubMed Web of Science ®Google Scholar
• Elyada E, Bolisetty M, Laise P, et al. Cross-species single-cell analysis of pancreatic ductal adenocarcinoma reveals antigen-presenting cancer-associated fibroblasts. Cancer Discov. 2019;9(8):1102–1123. doi:10.1158/2159-8290.CD-19-0094
   PubMed Web of Science ®Google Scholar
• Öhlund D, Handly-Santana A, Biffi G, et al. Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer. J Exp Med. 2017;214(3):579–596. doi:10.1084/jem.20162024
   PubMed Web of Science ®Google Scholar
• Omary MB, Lugea A, Lowe AW, et al. The pancreatic stellate cell: a star on the rise in pancreatic diseases. J Clin Invest. 2007;117(1):50–59. doi:10.1172/JCI30082
   PubMed Web of Science ®Google Scholar
• Yin C, Evason KJ, Asahina K, et al. Hepatic stellate cells in liver development, regeneration, and cancer. J Clin Invest. 2013;123(5):1902–1910. doi:10.1172/JCI66369
   PubMed Web of Science ®Google Scholar
• Nurmik M, Ullmann P, Rodriguez F, et al. In search of definitions: cancer-associated fibroblasts and their markers. Int J Cancer. 2020;146(4):895–905. doi:10.1002/ijc.32193
   PubMed Web of Science ®Google Scholar
• Whiteside TL. Exosome and mesenchymal stem cell cross-talk in the tumor microenvironment. Semin Immunol. 2018;35:69–79. doi:10.1016/j.smim.2017.12.003
   PubMed Web of Science ®Google Scholar
• Zhu Q, Zhang X, Zhang L, et al. The IL-6-STAT3 axis mediates a reciprocal crosstalk between cancer-derived mesenchymal stem cells and neutrophils to synergistically prompt gastric cancer progression. Cell Death Dis. 2014;5(6):e1295. doi:10.1038/cddis.2014.263
   PubMed Web of Science ®Google Scholar
• Zhang Q, Chai S, Wang W, et al. Macrophages activate mesenchymal stem cells to acquire cancer-associated fibroblast-like features resulting in gastric epithelial cell lesions and malignant transformation in vitro. Oncol Lett. 2019;17(1):747–756. doi:10.3892/ol.2018.9703
   PubMed Web of Science ®Google Scholar
• Shi Y, Du L, Lin L, et al. Tumour-associated mesenchymal stem/stromal cells: emerging therapeutic targets. Nat Rev Drug Discov. 2017;16(1):35–52. doi:10.1038/nrd.2016.193
   PubMed Web of Science ®Google Scholar
• Jotzu C, Alt E, Welte G, et al. Adipose tissue-derived stem cells differentiate into carcinoma-associated fibroblast-like cells under the influence of tumor-derived factors. Anal Cell Pathol (Amst). 2010;33(2):61–79. doi:10.1155/2010/695162
   PubMedGoogle Scholar
• Verginadis II, Avgousti H, Monslow J, et al. A stromal integrated stress response activates perivascular cancer-associated fibroblasts to drive angiogenesis and tumour progression. Nat Cell Biol. 2022;24(6):940–953. doi:10.1038/s41556-022-00918-8
   PubMed Web of Science ®Google Scholar
• Bhome R, Emaduddin M, James V, et al. Epithelial to mesenchymal transition influences fibroblast phenotype in colorectal cancer by altering miR-200 levels in extracellular vesicles. J Extracell Vesicles. 2022;11(5):e12226. doi:10.1002/jev2.12226
   PubMed Web of Science ®Google Scholar
• Mhaidly R, Mechta-Grigoriou F. Fibroblast heterogeneity in tumor micro-environment: role in immunosuppression and new therapies. Semin Immunol. 2020;48:101417. doi:10.1016/j.smim.2020.101417
   PubMed Web of Science ®Google Scholar
• Lavie D, Ben-Shmuel A, Erez N, et al. Cancer-associated fibroblasts in the single-cell era. Nat Cancer. 2022;3(7):793–807. doi:10.1038/s43018-022-00411-z
   PubMedGoogle Scholar
• Bartoschek M, Oskolkov N, Bocci M, et al. Spatially and functionally distinct subclasses of breast cancer-associated fibroblasts revealed by single cell RNA sequencing. Nat Commun. 2018;9(1):5150. doi:10.1038/s41467-018-07582-3
   PubMed Web of Science ®Google Scholar
• Liu T, Han C, Wang S, et al. Cancer-associated fibroblasts: an emerging target of anti-cancer immunotherapy. J Hematol Oncol. 2019;12(1):86. doi:10.1186/s13045-019-0770-1
   PubMed Web of Science ®Google Scholar
• Lakins MA, Ghorani E, Munir H, et al. Cancer-associated fibroblasts induce antigen-specific deletion of CD8 +T Cells to protect tumour cells. Nat Commun. 2018;9(1):948. doi:10.1038/s41467-018-03347-0
   PubMed Web of Science ®Google Scholar
• Darby IA, Zakuan N, Billet F, et al. The myofibroblast, a key cell in normal and pathological tissue repair. Cell Mol Life Sci. 2016;73(6):1145–1157. doi:10.1007/s00018-015-2110-0
   PubMed Web of Science ®Google Scholar
• Miyazaki Y, Oda T, Inagaki Y, et al. Adipose-derived mesenchymal stem cells differentiate into heterogeneous cancer-associated fibroblasts in a stroma-rich xenograft model. Sci Rep. 2021;11(1):4690. doi:10.1038/s41598-021-84058-3
   PubMed Web of Science ®Google Scholar
• Wang Y, Liang Y, Xu H, et al. Single-cell analysis of pancreatic ductal adenocarcinoma identifies a novel fibroblast subtype associated with poor prognosis but better immunotherapy response. Cell Discov. 2021;7(1):36. doi:10.1038/s41421-021-00271-4
   PubMed Web of Science ®Google Scholar
• Peng J, Sun B-F, Chen C-Y, et al. Single-cell RNA-seq highlights intra-tumoral heterogeneity and malignant progression in pancreatic ductal adenocarcinoma. Cell Res. 2019;29(9):725–738. doi:10.1038/s41422-019-0195-y
   PubMed Web of Science ®Google Scholar
• Friedman G, Levi-Galibov O, David E, et al. Cancer-associated fibroblast compositions change with breast cancer progression linking the ratio of S100A4(+) and PDPN(+) CAFs to clinical outcome. Nat Cancer. 2020;1(7):692–708. doi:10.1038/s43018-020-0082-y
   PubMedGoogle Scholar
• Kim N, Kim HK, Lee K, et al. Single-cell RNA sequencing demonstrates the molecular and cellular reprogramming of metastatic lung adenocarcinoma. Nat Commun. 2020;11(1):2285. doi:10.1038/s41467-020-16164-1
   PubMed Web of Science ®Google Scholar
• Lambrechts D, Wauters E, Boeckx B, et al. Phenotype molding of stromal cells in the lung tumor microenvironment. Nat Med. 2018;24(8):1277–1289. doi:10.1038/s41591-018-0096-5
   PubMed Web of Science ®Google Scholar
• Monteran L, Erez N. The dark side of fibroblasts: cancer-associated fibroblasts as mediators of immunosuppression in the tumor microenvironment. Front Immunol. 2019;10:1835. doi:10.3389/fimmu.2019.01835
   PubMed Web of Science ®Google Scholar
• Erez N, Truitt M, Olson P, et al. Cancer-associated fibroblasts are activated in incipient neoplasia to orchestrate tumor-promoting inflammation in an NF-kappaB-dependent manner. Cancer Cell. 2010;17(2):135–147. doi:10.1016/j.ccr.2009.12.041
   PubMed Web of Science ®Google Scholar
• Biffi G, Oni TE, Spielman B, et al. IL1-Induced JAK/STAT signaling is antagonized by TGFβ to Shape CAF heterogeneity in pancreatic ductal adenocarcinoma. Cancer Discov. 2019;9(2):282–301. doi:10.1158/2159-8290.CD-18-0710
   PubMed Web of Science ®Google Scholar
• Kwon OJ, Zhang Y, Li Y, et al. Functional heterogeneity of mouse prostate stromal cells revealed by Single-Cell RNA-Seq. iScience. 2019;13:328–338. doi:10.1016/j.isci.2019.02.032
   PubMed Web of Science ®Google Scholar
• Steele NG, Biffi G, Kemp SB, et al. Inhibition of hedgehog signaling alters fibroblast composition in pancreatic cancer. Clin Cancer Res. 2021;27(7):2023–2037. doi:10.1158/1078-0432.CCR-20-3715
   PubMed Web of Science ®Google Scholar
• Toullec A, Gerald D, Despouy G, et al. Oxidative stress promotes myofibroblast differentiation and tumour spreading. EMBO Mol Med. 2010;2(6):211–230. doi:10.1002/emmm.201000073
   PubMed Web of Science ®Google Scholar
• Zhang X, He C, He X, et al. HIF-1 inhibitor-based one-stone-two-birds strategy for enhanced cancer chemodynamic-immunotherapy. J Control Release. 2023;356:649–662. doi:10.1016/j.jconrel.2023.03.026
   PubMed Web of Science ®Google Scholar
• Zhang X, He C, Xiang G. Engineering nanomedicines to inhibit hypoxia-inducible Factor-1 for cancer therapy. Cancer Lett. 2022;530:110–127. doi:10.1016/j.canlet.2022.01.012
   PubMed Web of Science ®Google Scholar
• Kitamura F, Semba T, Yasuda-Yoshihara N, et al. Cancer-associated fibroblasts reuse cancer-derived lactate to maintain a fibrotic and immunosuppressive microenvironment in pancreatic cancer. JCI Insight. 2023;8(20). doi:10.1172/jci.insight.163022
   Web of Science ®Google Scholar
• Orimo A, Gupta PB, Sgroi DC, et al. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell. 2005;121(3):335–348. doi:10.1016/j.cell.2005.02.034
   PubMed Web of Science ®Google Scholar
• Olumi AF, Grossfeld GD, Hayward SW, et al. Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium. Cancer Res. 1999;59(19):5002–5011. doi:10.1186/bcr138
   PubMed Web of Science ®Google Scholar
• Unterleuthner D, Neuhold P, Schwarz K, et al. Cancer-associated fibroblast-derived WNT2 increases tumor angiogenesis in colon cancer. Angiogenesis. 2020;23(2):159–177. doi:10.1007/s10456-019-09688-8
   PubMed Web of Science ®Google Scholar
• Zhang F, Cui J-Y, Gao H-F, et al. Cancer-associated fibroblasts induce epithelial-mesenchymal transition and cisplatin resistance in ovarian cancer via CXCL12/CXCR4 axis. Future Oncol. 2020;16(32):2619–2633. doi:10.2217/fon-2020-0095
   PubMed Web of Science ®Google Scholar
• Glentis A, Oertle P, Mariani P, et al. Cancer-associated fibroblasts induce metalloprotease-independent cancer cell invasion of the basement membrane. Nat Commun. 2017;8(1):924. doi:10.1038/s41467-017-00985-8
   PubMed Web of Science ®Google Scholar
• Shintani Y, Fujiwara A, Kimura T, et al. IL-6 secreted from cancer-associated fibroblasts mediates chemoresistance in NSCLC by increasing epithelial-mesenchymal transition signaling. J Thorac Oncol. 2016;11(9):512–536. doi:10.1016/j.jtho.2016.05.025
   Web of Science ®Google Scholar
• Long X, Xiong W, Zeng X, et al. Cancer-associated fibroblasts promote cisplatin resistance in bladder cancer cells by increasing IGF-1/ERβ/Bcl-2 signalling. Cell Death Dis. 2019;10(5):375. doi:10.1038/s41419-019-1581-6
   PubMedGoogle Scholar
• Wang W, Kryczek I, Dostál L, et al. Effector T cells abrogate stroma-mediated chemoresistance in ovarian cancer. Cell. 2016;165(5):1092–1105. doi:10.1016/j.cell.2016.04.009
   PubMed Web of Science ®Google Scholar
• Yang M, McKay D, Pollard JW, et al. Diverse Functions of Macrophages in Different Tumor Microenvironments. Cancer Res. 2018;78(19):5492–5503. doi:10.1158/0008-5472.CAN-18-1367
   PubMed Web of Science ®Google Scholar
• Zhou X, Franklin RA, Adler M, et al. Circuit design features of a stable two-cell system. Cell. 2018;172(4):744–757.e17. doi:10.1016/j.cell.2018.01.015
   PubMed Web of Science ®Google Scholar
• Gok Yavuz B, Gunaydin G, Gedik ME, et al. Cancer associated fibroblasts sculpt tumour microenvironment by recruiting monocytes and inducing immunosuppressive PD-1+ TAMs. Sci Rep. 2019;9(1):3172. doi:10.1038/s41598-019-39553-z
   PubMedGoogle Scholar
• Buechler MB, Fu W, Turley SJ. Fibroblast-macrophage reciprocal interactions in health, fibrosis, and cancer. Immunity. 2021;54(5):903–915. doi:10.1016/j.immuni.2021.04.021
   PubMed Web of Science ®Google Scholar
• Velez-Delgado A, Donahue KL, Brown KL, et al. Extrinsic KRAS signaling shapes the pancreatic microenvironment through fibroblast reprogramming. Cell Mol Gastroenterol Hepatol. 2022;13(6):1673–1699. doi:10.1016/j.jcmgh.2022.02.016
   PubMed Web of Science ®Google Scholar
• Timperi E, Gueguen P, Molgora M, et al. Lipid-associated macrophages are induced by cancer-associated fibroblasts and mediate immune suppression in breast cancer. Cancer Res. 2022;82(18):3291–3306. doi:10.1158/0008-5472.CAN-22-1427
   PubMed Web of Science ®Google Scholar
• Suzuki J, Aokage K, Neri S, et al. Relationship between podoplanin-expressing cancer-associated fibroblasts and the immune microenvironment of early lung squamous cell carcinoma. Lung Cancer. 2021;153:1–10. doi:10.1016/j.lungcan.2020.12.020
   PubMed Web of Science ®Google Scholar
• Sakai T, Aokage K, Neri S, et al. Link between tumor-promoting fibrous microenvironment and an immunosuppressive microenvironment in stage I lung adenocarcinoma. Lung Cancer. 2018;126:64–71. doi:10.1016/j.lungcan.2018.10.021
   PubMed Web of Science ®Google Scholar
• Cho H, Seo Y, Loke KM, et al. Cancer-stimulated CAFs enhance monocyte differentiation and protumoral TAM Activation via IL6 and GM-CSF secretion. Clin Cancer Res. 2018;24(21):5407–5421. doi:10.1158/1078-0432.CCR-18-0125
   PubMed Web of Science ®Google Scholar
• Stadler M, Pudelko K, Biermeier A, et al. Stromal fibroblasts shape the myeloid phenotype in normal colon and colorectal cancer and induce CD163 and CCL2 expression in macrophages. Cancer Lett. 2021;520:184–200. doi:10.1016/j.canlet.2021.07.006
   PubMed Web of Science ®Google Scholar
• Zhang A, Qian Y, Ye Z, et al. Cancer-associated fibroblasts promote M2 polarization of macrophages in pancreatic ductal adenocarcinoma. Cancer Med. 2017;6(2):463–470. doi:10.1002/cam4.993
   PubMed Web of Science ®Google Scholar
• Li X, Sun Z, Peng G, et al. Single-cell RNA sequencing reveals a pro-invasive cancer-associated fibroblast subgroup associated with poor clinical outcomes in patients with gastric cancer. Theranostics. 2022;12(2):620–638. doi:10.7150/thno.60540
   PubMed Web of Science ®Google Scholar
• Cohen N, Shani O, Raz Y, et al. Fibroblasts drive an immunosuppressive and growth-promoting microenvironment in breast cancer via secretion of Chitinase 3-like 1. Oncogene. 2017;36(31):4457–4468. doi:10.1038/onc.2017.65
   PubMed Web of Science ®Google Scholar
• Maller O, Drain AP, Barrett AS, et al. Tumour-associated macrophages drive stromal cell-dependent collagen crosslinking and stiffening to promote breast cancer aggression. Nat Mater. 2021;20(4):548–559. doi:10.1038/s41563-020-00849-5
   PubMed Web of Science ®Google Scholar
• Gabrilovich DI. Myeloid-Derived Suppressor Cells. Cancer Immunol Res. 2017;5(1):3–8. doi:10.1158/2326-6066.CIR-16-0297
   PubMed Web of Science ®Google Scholar
• Xiang H, Ramil CP, Hai J, et al. Cancer-associated fibroblasts promote immunosuppression by inducing ROS-Generating Monocytic MDSCs in lung squamous cell carcinoma. Cancer Immunol Res. 2020;8(4):436–450. doi:10.1158/2326-6066.CIR-19-0507
   PubMed Web of Science ®Google Scholar
• Zhang R, Qi F, Zhao F, et al. Cancer-associated fibroblasts enhance tumor-associated macrophages enrichment and suppress NK cells function in colorectal cancer. Cell Death Dis. 2019;10(4):273. doi:10.1038/s41419-019-1435-2
   PubMed Web of Science ®Google Scholar
• Zhao Q, Huang L, Qin G, et al. Cancer-associated fibroblasts induce monocytic myeloid-derived suppressor cell generation via IL-6/exosomal miR-21-activated STAT3 signaling to promote cisplatin resistance in esophageal squamous cell carcinoma. Cancer Lett. 2021;518:35–48. doi:10.1016/j.canlet.2021.06.009
   PubMed Web of Science ®Google Scholar
• Wculek SK, Cueto FJ, Mujal AM, et al. Dendritic cells in cancer immunology and immunotherapy. Nat Rev Immunol. 2020;20(1):7–24. doi:10.1038/s41577-019-0210-z
   PubMed Web of Science ®Google Scholar
• Cheng JT, Deng Y-N, Yi H-M, et al. Hepatic carcinoma-associated fibroblasts induce IDO-producing regulatory dendritic cells through IL-6-mediated STAT3 activation. Oncogenesis. 2016;5(2):e198. doi:10.1038/oncsis.2016.7
   PubMedGoogle Scholar
• Berzaghi R, Tornaas S, Lode K, et al. Ionizing radiation curtails immunosuppressive effects from cancer-associated fibroblasts on dendritic cells. Front Immunol. 2021;12:662594. doi:10.3389/fimmu.2021.662594
   PubMed Web of Science ®Google Scholar
• Huang TX, Tan X-Y, Huang H-S, et al. Targeting cancer-associated fibroblast-secreted WNT2 restores dendritic cell-mediated antitumour immunity. Gut. 2022;71(2):333–344. doi:10.1136/gutjnl-2020-322924
   PubMed Web of Science ®Google Scholar
• Zhao P, Zhang Y, Li W, et al. Recent advances of antibody drug conjugates for clinical applications. Acta Pharm Sin B. 2020;10(9):1589–1600. doi:10.1016/j.apsb.2020.04.012
   PubMed Web of Science ®Google Scholar
• Ziani L, Chouaib S, Thiery J. Alteration of the antitumor immune response by cancer-associated fibroblasts. Front Immunol. 2018;9:414. doi:10.3389/fimmu.2018.00414
   PubMed Web of Science ®Google Scholar
• Santos AM, Jung J, Aziz N, et al. Targeting fibroblast activation protein inhibits tumor stromagenesis and growth in mice. J Clin Invest. 2009;119(12):3613–3625. doi:10.1172/JCI38988
   PubMed Web of Science ®Google Scholar
• Scott AM, Wiseman G, Welt S, et al. A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer. Clin Cancer Res. 2003;9(5):1639–1647.
   PubMed Web of Science ®Google Scholar
• Qian L, Tang Z, Yin S, et al. Fusion of dendritic cells and cancer-associated fibroblasts for activation of anti-tumor cytotoxic T lymphocytes. J Biomed Nanotechnol. 2018;14(10):1826–1835. doi:10.1166/jbn.2018.2616
   PubMed Web of Science ®Google Scholar
• Xia Q, Zhang -F-F, Geng F, et al. Anti-tumor effects of DNA vaccine targeting human fibroblast activation protein α by producing specific immune responses and altering tumor microenvironment in the 4T1 murine breast cancer model. Cancer Immunol Immunother. 2016;65(5):613–624. doi:10.1007/s00262-016-1827-4
   PubMed Web of Science ®Google Scholar
• Kraman M, Bambrough PJ, Arnold JN, et al. Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-alpha. Science. 2010;330(6005):827–830. doi:10.1126/science.1195300
   PubMed Web of Science ®Google Scholar
• Cancer Discovery. FAP-Targeted 4-1BB agonist tamps down advanced tumors. Cancer Discov. 2023;13(8):Of2. doi:10.1158/2159-8290.CD-NB2023-0044
   Google Scholar
• Hofheinz RD, al-Batran S-E, Hartmann F, et al. Stromal antigen targeting by a humanised monoclonal antibody: an early phase II trial of sibrotuzumab in patients with metastatic colorectal cancer. Onkologie. 2003;26(1):44–48. doi:10.1159/000069863
   PubMedGoogle Scholar
• Cunningham CC. Talabostat. Expert Opin Investig Drugs. 2007;16(9):1459–1465. doi:10.1517/13543784.16.9.1459
   PubMed Web of Science ®Google Scholar
• Roberts EW, Deonarine A, Jones JO, et al. Depletion of stromal cells expressing fibroblast activation protein-α from skeletal muscle and bone marrow results in cachexia and anemia. J Exp Med. 2013;210(6):1137–1151. doi:10.1084/jem.20122344
   PubMed Web of Science ®Google Scholar
• Özdemir BC, Pentcheva-Hoang T, Carstens JL, et al. Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. Cancer Cell. 2015;28(6):831–833. doi:10.1016/j.ccell.2015.11.002
   PubMed Web of Science ®Google Scholar
• Wei Y, Kim TJ, Peng DH, et al. Fibroblast-specific inhibition of TGF-β1 signaling attenuates lung and tumor fibrosis. J Clin Invest. 2017;127(10):3675–3688. doi:10.1172/JCI94624
   PubMed Web of Science ®Google Scholar
• Mariathasan S, Turley SJ, Nickles D, et al. TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature. 2018;554(7693):544–548. doi:10.1038/nature25501
   PubMed Web of Science ®Google Scholar
• Faivre S, Santoro A, Kelley RK, et al. Novel transforming growth factor beta receptor I kinase inhibitor galunisertib (LY2157299) in advanced hepatocellular carcinoma. Liver Int. 2019;39(8):1468–1477. doi:10.1111/liv.14113
   PubMed Web of Science ®Google Scholar
• Carapuça EF, Gemenetzidis E, Feig C, et al. Anti-stromal treatment together with chemotherapy targets multiple signalling pathways in pancreatic adenocarcinoma. J Pathol. 2016;239(3):286–296. doi:10.1002/path.4727
   PubMed Web of Science ®Google Scholar
• Sherman MH, Yu R, Engle D, et al. Vitamin D receptor-mediated stromal reprogramming suppresses pancreatitis and enhances pancreatic cancer therapy. Cell. 2014;159(1):80–93. doi:10.1016/j.cell.2014.08.007
   PubMed Web of Science ®Google Scholar
• Ene-Obong A, Clear AJ, Watt J, et al. Activated pancreatic stellate cells sequester CD8+ T cells to reduce their infiltration of the juxtatumoral compartment of pancreatic ductal adenocarcinoma. Gastroenterology. 2013;145(5):1121–1132. doi:10.1053/j.gastro.2013.07.025
   PubMed Web of Science ®Google Scholar
• Ishihara S, Inman DR, Li W-J, et al. Mechano-signal transduction in mesenchymal stem cells induces prosaposin secretion to drive the proliferation of breast cancer cells. Cancer Res. 2017;77(22):6179–6189. doi:10.1158/0008-5472.CAN-17-0569
   PubMed Web of Science ®Google Scholar
• Gorchs L, Ahmed S, Mayer C, et al. The vitamin D analogue calcipotriol promotes an anti-tumorigenic phenotype of human pancreatic CAFs but reduces T cell mediated immunity. Sci Rep. 2020;10(1):17444. doi:10.1038/s41598-020-74368-3
   PubMed Web of Science ®Google Scholar
• Li X, Yong T, Wei Z, et al. Reversing insufficient photothermal therapy-induced tumor relapse and metastasis by regulating cancer-associated fibroblasts. Nat Commun. 2022;13(1):2794. doi:10.1038/s41467-022-30306-7
   PubMed Web of Science ®Google Scholar
• Wang X, Dai G, Jiang G, et al. A TMVP1-modified near-infrared nanoprobe: molecular imaging for tumor metastasis in sentinel lymph node and targeted enhanced photothermal therapy. J Nanobiotechnology. 2023;21(1):130. doi:10.1186/s12951-023-01883-6
   PubMed Web of Science ®Google Scholar
• Feig C, Jones JO, Kraman M, et al. Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer. Proc Natl Acad Sci U S A. 2013;110(50):20212–20217. doi:10.1073/pnas.1320318110
   PubMed Web of Science ®Google Scholar
• Hurwitz HI, Uppal N, Wagner SA, et al. Randomized, double-blind, phase ii study of ruxolitinib or placebo in combination with capecitabine in patients with metastatic pancreatic cancer for whom therapy with gemcitabine has failed. J Clin Oncol. 2015;33(34):4039–4047. doi:10.1200/JCO.2015.61.4578
   PubMed Web of Science ®Google Scholar
• Cazet AS, Hui MN, Elsworth BL, et al. Targeting stromal remodeling and cancer stem cell plasticity overcomes chemoresistance in triple negative breast cancer. Nat Commun. 2018;9(1):2897. doi:10.1038/s41467-018-05220-6
   PubMedGoogle Scholar
• Olive KP, Jacobetz MA, Davidson CJ, et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science. 2009;324(5933):1457–1461. doi:10.1126/science.1171362
   PubMed Web of Science ®Google Scholar
• Kim EJ, Sahai V, Abel EV, et al. Pilot clinical trial of hedgehog pathway inhibitor GDC-0449 (vismodegib) in combination with gemcitabine in patients with metastatic pancreatic adenocarcinoma. Clin Cancer Res. 2014;20(23):5937–5945. doi:10.1158/1078-0432.CCR-14-1269
   PubMed Web of Science ®Google Scholar
• Huang Y, Simms AE, Mazur A, et al. Fibroblast activation protein-α promotes tumor growth and invasion of breast cancer cells through non-enzymatic functions. Clin Exp Metastasis. 2011;28(6):567–579. doi:10.1007/s10585-011-9392-x
   PubMed Web of Science ®Google Scholar
• Li J, Kataoka K. Chemo-physical strategies to advance the in vivo functionality of targeted nanomedicine: the next generation. J Am Chem Soc. 2021;143(2):538–559. doi:10.1021/jacs.0c09029
   PubMed Web of Science ®Google Scholar
• Wen P, Ke W, Dirisala A, et al. Stealth and pseudo-stealth nanocarriers. Adv Drug Deliv Rev. 2023;198:114895. doi:10.1016/j.addr.2023.114895
   PubMed Web of Science ®Google Scholar
• Ikeda-Imafuku M, Wang LL-W, Rodrigues D, et al. Strategies to improve the EPR effect: a mechanistic perspective and clinical translation. J Control Release. 2022;345:512–536. doi:10.1016/j.jconrel.2022.03.043
   PubMed Web of Science ®Google Scholar
• Sun R, Xiang J, Zhou Q, et al. The tumor EPR effect for cancer drug delivery: current status, limitations, and alternatives. Adv Drug Deliv Rev. 2022;191:114614. doi:10.1016/j.addr.2022.114614
   PubMed Web of Science ®Google Scholar
• Sindhwani S, Syed AM, Ngai J, et al. The entry of nanoparticles into solid tumours. Nat Mater. 2020;19(5):566–575. doi:10.1038/s41563-019-0566-2
   PubMed Web of Science ®Google Scholar
• Peng F, Setyawati MI, Tee JK, et al. Nanoparticles promote in vivo breast cancer cell intravasation and extravasation by inducing endothelial leakiness. Nat Nanotechnol. 2019;14(3):279–286. doi:10.1038/s41565-018-0356-z
   PubMed Web of Science ®Google Scholar
• Guo J, Zeng H, Shi X, et al. A CFH peptide-decorated liposomal oxymatrine inactivates cancer-associated fibroblasts of hepatocellular carcinoma through epithelial-mesenchymal transition reversion. J Nanobiotechnology. 2022;20(1):114. doi:10.1186/s12951-022-01311-1
   PubMed Web of Science ®Google Scholar
• Chen B, Wang Z, Sun J, et al. A tenascin C targeted nanoliposome with navitoclax for specifically eradicating of cancer-associated fibroblasts. Nanomedicine. 2016;12(1):131–141. doi:10.1016/j.nano.2015.10.001
   PubMed Web of Science ®Google Scholar
• Chen B, Dai W, Mei D, et al. Comprehensively priming the tumor microenvironment by cancer-associated fibroblast-targeted liposomes for combined therapy with cancer cell-targeted chemotherapeutic drug delivery system. J Control Release. 2016;241:68–80. doi:10.1016/j.jconrel.2016.09.014
   PubMed Web of Science ®Google Scholar
• Fourniols T, Bastien E, Canevat A, et al. Inhibition of colorectal cancer-associated fibroblasts by lipid nanocapsules loaded with acriflavine or paclitaxel. Int J Pharm. 2020;584:119337. doi:10.1016/j.ijpharm.2020.119337
   PubMed Web of Science ®Google Scholar
• Hou L, Liu Q, Shen L, et al. Nano-delivery of fraxinellone remodels tumor microenvironment and facilitates therapeutic vaccination in desmoplastic melanoma. Theranostics. 2018;8(14):3781–3796. doi:10.7150/thno.24821
   PubMed Web of Science ®Google Scholar
• Chen Y, Hu M, Wang S, et al. Nano-delivery of salvianolic acid B induces the quiescence of tumor-associated fibroblasts via interfering with TGF-beta1/Smad signaling to facilitate chemo- and immunotherapy in desmoplastic tumor. Int J Pharm. 2022;623:121953. doi:10.1016/j.ijpharm.2022.121953
   PubMedGoogle Scholar
• Miao L, Liu Q, Lin CM, et al. Targeting tumor-associated fibroblasts for therapeutic delivery in desmoplastic tumors. Cancer Res. 2017;77(3):719–731. doi:10.1158/0008-5472.CAN-16-0866
   PubMed Web of Science ®Google Scholar
• Tan Y-N, Li Y-P, Huang J-D, et al. Thermal-sensitive lipid nanoparticles potentiate anti-PD therapy through enhancing drug penetration and T lymphocytes infiltration in metastatic tumor. Cancer Letters. 2021;522:238–254. doi:10.1016/j.canlet.2021.09.031
   PubMed Web of Science ®Google Scholar
• Li Y, Wu J, Lu Q, et al. GA&HA-modified liposomes for co-delivery of aprepitant and curcumin to inhibit drug-resistance and metastasis of hepatocellular carcinoma. Int J Nanomedicine. 2022;17:2559–2575. doi:10.2147/IJN.S366180
   PubMed Web of Science ®Google Scholar
• Wu J, Qi C, Wang H, et al. Curcumin and berberine co-loaded liposomes for anti-hepatocellular carcinoma therapy by blocking the cross-talk between hepatic stellate cells and tumor cells. Front Pharmacol. 2022;13:961788. doi:10.3389/fphar.2022.961788
   PubMed Web of Science ®Google Scholar
• Li X, Luo Y, Huang Z, et al. Multifunctional liposomes remodeling tumor immune microenvironment for tumor chemoimmunotherapy. Small Methods. 2023;7(5):e2201327. doi:10.1002/smtd.202201327
   PubMed Web of Science ®Google Scholar
• Ferraz FS, Lopez JL, Lacerda SM, et al. Biotechnological approach to induce human fibroblast apoptosis using superparamagnetic iron oxide nanoparticles. J Inorg Biochem. 2020;206:111017.
   PubMed Web of Science ®Google Scholar
• Kovacs D, Igaz N, Marton A, et al. Core-shell nanoparticles suppress metastasis and modify the tumour-supportive activity of cancer-associated fibroblasts. J Nanobiotechnology. 2020;18(1):18. doi:10.1186/s12951-020-0576-x
   PubMed Web of Science ®Google Scholar
• Dilnawaz F, Singh A, Mohanty C, et al. Dual drug loaded superparamagnetic iron oxide nanoparticles for targeted cancer therapy. Biomaterials. 2010;31(13):3694–3706. doi:10.1016/j.biomaterials.2010.01.057
   PubMed Web of Science ®Google Scholar
• Mardhian DF, Vrynas A, Storm G, et al. FGF2 engineered SPIONs attenuate tumor stroma and potentiate the effect of chemotherapy in 3D heterospheroidal model of pancreatic tumor. Nanotheranostics. 2020;4(1):26–39. doi:10.7150/ntno.38092
   PubMedGoogle Scholar
• Xia C, Pan J, Wang J, et al. Functional blockade of cancer-associated fibroblasts with ultrafine gold nanomaterials causes an unprecedented bystander antitumoral effect. Nanoscale. 2020;12(38):19833–19843. doi:10.1039/D0NR04682E
   PubMed Web of Science ®Google Scholar
• Hossen MN, Rao G, Dey A, et al. Gold nanoparticle transforms activated cancer-associated fibroblasts to quiescence. ACS Appl Mater Interfaces. 2019;11(29):26060–26068. doi:10.1021/acsami.9b03313
   PubMed Web of Science ®Google Scholar
• Zhang Y, Elechalawar CK, Hossen MN, et al. Gold nanoparticles inhibit activation of cancer-associated fibroblasts by disrupting communication from tumor and microenvironmental cells. Bioact Mater. 2021;6(2):326–332. doi:10.1016/j.bioactmat.2020.08.009
   PubMed Web of Science ®Google Scholar
• Zheng D, Wan C, Yang H, et al. Her2-targeted multifunctional nano-theranostic platform mediates tumor microenvironment remodeling and immune activation for breast cancer treatment. Int J Nanomedicine. 2020;15:10007–10028. doi:10.2147/IJN.S271213
   PubMed Web of Science ®Google Scholar
• Dadfar SM, Roemhild K, Drude NI, et al. Iron oxide nanoparticles: diagnostic, therapeutic and theranostic applications. Adv Drug Deliv Rev. 2019;138:302–325. doi:10.1016/j.addr.2019.01.005
   PubMed Web of Science ®Google Scholar
• Nicolas-Boluda A, Vaquero J, Laurent G, et al. Photothermal depletion of cancer-associated fibroblasts normalizes tumor stiffness in desmoplastic cholangiocarcinoma. ACS Nano. 2020;14(5):5738–5753. doi:10.1021/acsnano.0c00417
   PubMed Web of Science ®Google Scholar
• Wang Y, Xia H, Chen B, et al. Rethinking nanoparticulate polymer-drug conjugates for cancer theranostics. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2023;15(1):e1828. doi:10.1002/wnan.1828
   PubMed Web of Science ®Google Scholar
• Zuo T, Zhang J, Yang J, et al. On-demand responsive nanoplatform mediated targeting of CAFs and down-regulating mtROS-PYK2 signaling for antitumor metastasis. Biomater Sci. 2021;9(5):1872–1885. doi:10.1039/D0BM01878C
   PubMed Web of Science ®Google Scholar
• Donthireddy L, Vonteddu P, Murthy T, et al. ONP-302 nanoparticles inhibit tumor growth by altering tumor-associated macrophages and cancer-associated fibroblasts. Journal of Cancer. 2022;13(6):1933–1944. doi:10.7150/jca.69338
   PubMed Web of Science ®Google Scholar
• Getts DR, Terry RL, Getts MT, et al. Therapeutic inflammatory monocyte modulation using immune-modifying microparticles. Sci Transl Med. 2014;6(219):219ra7. doi:10.1126/scitranslmed.3007563
   PubMed Web of Science ®Google Scholar
• Zheng S, Wang J, Ding N, et al. Prodrug polymeric micelles integrating cancer-associated fibroblasts deactivation and synergistic chemotherapy for gastric cancer. J Nanobiotechnology. 2021;19(1):381. doi:10.1186/s12951-021-01127-5
   PubMed Web of Science ®Google Scholar
• Zhao J, Wang H, Hsiao C-H, et al. Simultaneous inhibition of hedgehog signaling and tumor proliferation remodels stroma and enhances pancreatic cancer therapy. Biomaterials. 2018;159:215–228. doi:10.1016/j.biomaterials.2018.01.014
   PubMed Web of Science ®Google Scholar
• Zhou C, Hu X, Liu Q, et al. Stromal barrier-dismantled nanodrill-like and cancer cell-targeted pH-responsive polymeric micelles for further enhancing the anticancer efficacy of doxorubicin. ACS Biomater Sci Eng. 2021;7(12):5690–5705. doi:10.1021/acsbiomaterials.1c01131
   PubMed Web of Science ®Google Scholar
• Monteiro PF, Gulfam M, Monteiro CJ, et al. Synthesis of micellar-like terpolymer nanoparticles with reductively-cleavable cross-links and evaluation of efficacy in 2D and 3D models of triple negative breast cancer. J Control Release. 2020;323:549–564. doi:10.1016/j.jconrel.2020.04.049
   PubMed Web of Science ®Google Scholar
• Ernsting MJ, Hoang B, Lohse I, et al. Targeting of metastasis-promoting tumor-associated fibroblasts and modulation of pancreatic tumor-associated stroma with a carboxymethylcellulose-docetaxel nanoparticle. J Control Release. 2015;206:122–130. doi:10.1016/j.jconrel.2015.03.023
   PubMed Web of Science ®Google Scholar
• Wang L, Liu X, Zhou Q, et al. Terminating the criminal collaboration in pancreatic cancer: nanoparticle-based synergistic therapy for overcoming fibroblast-induced drug resistance. Biomaterials. 2017;144:105–118. doi:10.1016/j.biomaterials.2017.08.002
   PubMed Web of Science ®Google Scholar
• Hou L, Chen D, Hao L, et al. Transformable nanoparticles triggered by cancer-associated fibroblasts for improving drug permeability and efficacy in desmoplastic tumors. Nanoscale. 2019;11(42):20030–20044. doi:10.1039/C9NR06438A
   PubMed Web of Science ®Google Scholar
• Ji T, Zhao Y, Ding Y, et al. Transformable peptide nanocarriers for expeditious drug release and effective cancer therapy via cancer-associated fibroblast activation. Angew Chem Int Ed Engl. 2016;55(3):1050–1055. doi:10.1002/anie.201506262
   PubMed Web of Science ®Google Scholar
• Huo M, Zhao Y, Satterlee AB, et al. Tumor-targeted delivery of sunitinib base enhances vaccine therapy for advanced melanoma by remodeling the tumor microenvironment. J Control Release. 2017;245:81–94. doi:10.1016/j.jconrel.2016.11.013
   PubMed Web of Science ®Google Scholar
• Panagi M, Mpekris F, Chen P, et al. Polymeric micelles effectively reprogram the tumor microenvironment to potentiate nano-immunotherapy in mouse breast cancer models. Nat Commun. 2022;13(1):7165. doi:10.1038/s41467-022-34744-1
   PubMed Web of Science ®Google Scholar
• Shen W, Yao P-A, Li W, et al. Cancer-associated fibroblast-targeted nanodrugs reshape colorectal tumor microenvironments to suppress tumor proliferation, metastasis and improve drug penetration. J Mater Chem B. 2023;11(9):1871–1880. doi:10.1039/D2TB02253B
   PubMed Web of Science ®Google Scholar
• Zheng F, Luo Y, Liu Y, et al. Nano-baicalein facilitates chemotherapy in breast cancer by targeting tumor microenvironment. Int J Pharm. 2023;635:122778. doi:10.1016/j.ijpharm.2023.122778
   PubMedGoogle Scholar
• Tang Y, Yao W, Hu H, et al. TGF-beta blocking combined with photothermal therapy promote tumor targeted migration and long-term antitumor activity of CAR-T cells. Mater Today Bio. 2023;20:100615. doi:10.1016/j.mtbio.2023.100615
   PubMedGoogle Scholar
• Zhou S, Zhen Z, Paschall AV, et al. FAP-targeted photodynamic therapy mediated by ferritin nanoparticles elicits an immune response against cancer cells and cancer associated fibroblasts. Adv Funct Mater. 2021;31(7). doi:10.1002/adfm.202007017
   Web of Science ®Google Scholar
• Li L, Zhou S, Lv N, et al. Photosensitizer-encapsulated ferritins mediate photodynamic therapy against cancer-associated fibroblasts and improve tumor accumulation of nanoparticles. Mol Pharm. 2018;15(8):3595–3599. doi:10.1021/acs.molpharmaceut.8b00419
   PubMedGoogle Scholar
• Sitia L, Bonizzi A, Mazzucchelli S, et al. Selective Targeting of Cancer-Associated Fibroblasts by Engineered H-Ferritin Nanocages Loaded with Navitoclax. Cells. 2021;10(2):328. doi:10.3390/cells10020328
   PubMed Web of Science ®Google Scholar
• Yu Q, Qiu Y, Li J, et al. Targeting cancer-associated fibroblasts by dual-responsive lipid-albumin nanoparticles to enhance drug perfusion for pancreatic tumor therapy. J Control Release. 2020;321:564–575. doi:10.1016/j.jconrel.2020.02.040
   PubMed Web of Science ®Google Scholar
• Li J, Zhen X, Lyu Y, et al. Cell membrane coated semiconducting polymer nanoparticles for enhanced multimodal cancer phototheranostics. ACS Nano. 2018;12(8):8520–8530. doi:10.1021/acsnano.8b04066
   PubMed Web of Science ®Google Scholar
• Tan YN, Huang J-D, Li Y-P, et al. Near-infrared responsive membrane nanovesicles amplify homologous targeting delivery of anti-PD immunotherapy against metastatic tumors. Adv Healthc Mater. 2022;11(6):e2101496. doi:10.1002/adhm.202101496
   PubMed Web of Science ®Google Scholar
• Zhao T, Zhang R, He Q, et al. Partial ligand shielding nanoparticles improve pancreatic ductal adenocarcinoma treatment via a multifunctional paradigm for tumor stroma reprogramming. Acta Biomater. 2022;145:122–134. doi:10.1016/j.actbio.2022.03.050
   PubMed Web of Science ®Google Scholar
• Yingchoncharoen P, Kalinowski DS, Richardson DR. Lipid-based drug delivery systems in cancer therapy: what is available and what is yet to come. Pharmacol Rev. 2016;68(3):701–787. doi:10.1124/pr.115.012070
   PubMed Web of Science ®Google Scholar
• Saw PE, Park J, Lee E, et al. Effect of PEG pairing on the efficiency of cancer-targeting liposomes. Theranostics. 2015;5(7):746–754. doi:10.7150/thno.10732
   PubMed Web of Science ®Google Scholar
• Sonju JJ, Dahal A, Singh SS, et al. Peptide-functionalized liposomes as therapeutic and diagnostic tools for cancer treatment. J Control Release. 2021;329:624–644. doi:10.1016/j.jconrel.2020.09.055
   PubMed Web of Science ®Google Scholar
• Zhao L, Chen J, Pang Y, et al. Fibroblast activation protein-based theranostics in cancer research: a state-of-The-art review. Theranostics. 2022;12(4):1557–1569. doi:10.7150/thno.69475
   PubMed Web of Science ®Google Scholar
• Yilmaz A, Loustau T, Salomé N, et al. Advances on the roles of tenascin-C in cancer. J Cell Sci. 2022;135(18). doi:10.1242/jcs.260244
   PubMed Web of Science ®Google Scholar
• Kim MY, Kim OR, Choi YS, et al. Selection and characterization of tenascin C targeting peptide. Mol Cells. 2012;33(1):71–77. doi:10.1007/S10059-012-2214-4
   PubMed Web of Science ®Google Scholar
• Huynh NT, Passirani C, Saulnier P, et al. Lipid nanocapsules: a new platform for nanomedicine. Int J Pharm. 2009;379(2):201–209. doi:10.1016/j.ijpharm.2009.04.026
   PubMed Web of Science ®Google Scholar
• Hu H, Xu Q, Mo Z, et al. New anti-cancer explorations based on metal ions. J Nanobiotechnology. 2022;20(1):457. doi:10.1186/s12951-022-01661-w
   PubMed Web of Science ®Google Scholar
• Singh P, Pandit S, Mokkapati VRSS, et al. Gold nanoparticles in diagnostics and therapeutics for human cancer. Int J Mol Sci. 2018;19(7):1979. doi:10.3390/ijms19071979
   PubMed Web of Science ®Google Scholar
• Alhussan A, Bromma K, Perez MM, et al. Docetaxel-mediated uptake and retention of gold nanoparticles in tumor cells and in cancer-associated fibroblasts. Cancers (Basel). 2021;13(13):3157. doi:10.3390/cancers13133157
   PubMed Web of Science ®Google Scholar
• Alhussan A, Palmerley N, Smazynski J, et al. Potential of gold nanoparticle in current radiotherapy using a co-culture model of cancer cells and cancer associated fibroblast cells. Cancers (Basel). 2022;14(15):3586. doi:10.3390/cancers14153586
   PubMed Web of Science ®Google Scholar
• Park EJ, Yi J, Kim Y, et al. Silver nanoparticles induce cytotoxicity by a Trojan-horse type mechanism. Toxicol In Vitro. 2010;24(3):872–878. doi:10.1016/j.tiv.2009.12.001
   PubMed Web of Science ®Google Scholar
• Santhosh PB, Ulrih NP. Multifunctional superparamagnetic iron oxide nanoparticles: promising tools in cancer theranostics. Cancer Lett. 2013;336(1):8–17. doi:10.1016/j.canlet.2013.04.032
   PubMed Web of Science ®Google Scholar
• Lopez S, Hallali N, Lalatonne Y, et al. Magneto-mechanical destruction of cancer-associated fibroblasts using ultra-small iron oxide nanoparticles and low frequency rotating magnetic fields. Nanoscale Adv. 2022;4(2):421–436. doi:10.1039/D1NA00474C
   PubMed Web of Science ®Google Scholar
• Mardhian DF, Storm G, Bansal R, et al. Nano-targeted relaxin impairs fibrosis and tumor growth in pancreatic cancer and improves the efficacy of gemcitabine in vivo. J Control Release. 2018;290:1–10. doi:10.1016/j.jconrel.2018.09.031
   PubMed Web of Science ®Google Scholar
• Ghosh B, Biswas S. Polymeric micelles in cancer therapy: state of the art. J Control Release. 2021;332:127–147. doi:10.1016/j.jconrel.2021.02.016
   PubMed Web of Science ®Google Scholar
• Masood F. Polymeric nanoparticles for targeted drug delivery system for cancer therapy. Mater Sci Eng C Mater Biol Appl. 2016;60:569–578. doi:10.1016/j.msec.2015.11.067
   PubMed Web of Science ®Google Scholar
• Acharya S, Sahoo SK. PLGA nanoparticles containing various anticancer agents and tumour delivery by EPR effect. Adv Drug Deliv Rev. 2011;63(3):170–183. doi:10.1016/j.addr.2010.10.008
   PubMed Web of Science ®Google Scholar
• Liu J, He S, Luo Y, et al. Tumor-microenvironment-activatable polymer nano-immunomodulator for precision cancer photoimmunotherapy. Adv Mater. 2022;34(8):e2106654. doi:10.1002/adma.202106654
   PubMed Web of Science ®Google Scholar
• Sun X, Hong Y, Gong Y, et al. Bioengineered ferritin nanocarriers for cancer therapy. Int J Mol Sci. 2021;22:13.
   Web of Science ®Google Scholar
• Truffi M, Fiandra L, Sorrentino L, et al. Ferritin nanocages: a biological platform for drug delivery, imaging and theranostics in cancer. Pharmacol Res. 2016;107:57–65. doi:10.1016/j.phrs.2016.03.002
   PubMed Web of Science ®Google Scholar
• Kang S, Oltrogge LM, Broomell CC, et al. Controlled assembly of bifunctional chimeric protein cages and composition analysis using noncovalent mass spectrometry. J Am Chem Soc. 2008;130(49):16527–16529. doi:10.1021/ja807655t
   PubMed Web of Science ®Google Scholar
• Belletti D, Pederzoli F, Forni F, et al. Protein cage nanostructure as drug delivery system: magnifying glass on apoferritin. Expert Opin Drug Deliv. 2017;14(7):825–840. doi:10.1080/17425247.2017.1243528
   PubMed Web of Science ®Google Scholar
• Choi B, Park W, Park S-B, et al. Recent trends in cell membrane-cloaked nanoparticles for therapeutic applications. Methods. 2020;177:2–14. doi:10.1016/j.ymeth.2019.12.004
   PubMed Web of Science ®Google Scholar
• Zhen X, Cheng P, Pu K. Recent advances in cell membrane-camouflaged nanoparticles for cancer phototherapy. Small. 2019;15(1):e1804105. doi:10.1002/smll.201804105
   PubMed Web of Science ®Google Scholar
• Chen HY, Deng J, Wang Y, et al. Hybrid cell membrane-coated nanoparticles: a multifunctional biomimetic platform for cancer diagnosis and therapy. Acta Biomater. 2020;112:1–13. doi:10.1016/j.actbio.2020.05.028
   PubMed Web of Science ®Google Scholar
• Wang L, Wu M, Pan Y, et al. Sequential targeting biomimetic nano platform for enhanced mild photothermal therapy and chemotherapy of tumor. Comput Struct Biotechnol J. 2023;21:2780–2791. doi:10.1016/j.csbj.2023.04.024
   PubMed Web of Science ®Google Scholar
• Zang S, Huang K, Li J, et al. Metabolic reprogramming by dual-targeting biomimetic nanoparticles for enhanced tumor chemo-immunotherapy. Acta Biomater. 2022;148:181–193. doi:10.1016/j.actbio.2022.05.045
   PubMed Web of Science ®Google Scholar
• Hamson EJ, Keane FM, Tholen S, et al. Understanding fibroblast activation protein (FAP): substrates, activities, expression and targeting for cancer therapy. Proteomics Clin Appl. 2014;8(5–6):454–463. doi:10.1002/prca.201300095
   PubMed Web of Science ®Google Scholar
• Shin H, Kim Y, Jon S. Nanovaccine displaying immunodominant T cell epitopes of fibroblast activation protein is effective against desmoplastic tumors. ACS Nano. 2023;17(11):10337–10352. doi:10.1021/acsnano.3c00764
   PubMed Web of Science ®Google Scholar
• Guo C, Zhang W, Zhang Q, et al. Novel dual CAFs and tumour cell targeting pH and ROS dual sensitive micelles for targeting delivery of paclitaxel to liver cancer. Artif Cells Nanomed Biotechnol. 2023;51(1):170–179. doi:10.1080/21691401.2023.2193221
   PubMed Web of Science ®Google Scholar
• Rhim AD, Oberstein P, Thomas D, et al. Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma. Cancer Cell. 2014;25(6):735–747. doi:10.1016/j.ccr.2014.04.021
   PubMed Web of Science ®Google Scholar
• Rajurkar M, De Jesus-Monge WE, Driscoll DR, et al. The activity of Gli transcription factors is essential for Kras-induced pancreatic tumorigenesis. Proc Natl Acad Sci U S A. 2012;109(17):E1038–47. doi:10.1073/pnas.1114168109
   PubMed Web of Science ®Google Scholar
• Cheng Y, Zou J, He M, et al. Spatiotemporally controlled Pseudomonas exotoxin transgene system combined with multifunctional nanoparticles for breast cancer antimetastatic therapy. J Control Release. 2023;367:167–83.
   Web of Science ®Google Scholar
• Tu Y, Zhang W, Fan G, et al. Paclitaxel-loaded ROS-responsive nanoparticles for head and neck cancer therapy. Drug Deliv. 2023;30(1):2189106. doi:10.1080/10717544.2023.2189106
   PubMed Web of Science ®Google Scholar
• Souers AJ, Leverson JD, Boghaert ER, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med. 2013;19(2):202–208. doi:10.1038/nm.3048
   PubMed Web of Science ®Google Scholar
• Chen J, Jin S, Abraham V, et al. The Bcl-2/Bcl-XL/Bcl-w Inhibitor, Navitoclax, enhances the activity of chemotherapeutic agents in vitro and in vivo. Mol Cancer Ther. 2011;10(12):2340–2349. doi:10.1158/1535-7163.MCT-11-0415
   PubMed Web of Science ®Google Scholar
• Gandhi L, Camidge DR, Ribeiro de oliveira M, et al. Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors. J Clin Oncol. 2011;29(7):909–916. doi:10.1200/JCO.2010.31.6208
   PubMed Web of Science ®Google Scholar
• Luo J, Zhang P, Zhao T, et al. Golgi apparatus-targeted chondroitin-modified nanomicelles suppress hepatic stellate cell activation for the management of liver fibrosis. ACS Nano. 2019;13(4):3910–3923. doi:10.1021/acsnano.8b06924
   PubMed Web of Science ®Google Scholar
• Liu H, Wu J, Qi C, et al. pH-responsive sulfated hyaluronic acid nanoparticles targeting tumor cells and CAFs for the treatment of breast cancer. Recent Pat Anti-Cancer Drug Disc. 2023;18(2):200–210. doi:10.2174/1574892817666220510123820
   Web of Science ®Google Scholar
• Zou C, Tang Y, Zeng P, et al. cRGD-modified nanoparticles of multi-bioactive agent conjugate with pH-sensitive linkers and PD-L1 antagonist for integrative collaborative treatment of breast cancer. Nanoscale Horiz. 2023;8(7):870–886. doi:10.1039/D2NH00590E
   PubMed Web of Science ®Google Scholar
• Jin J, Krishnamachary B, Barnett JD, et al. Human cancer cell membrane-coated biomimetic nanoparticles reduce fibroblast-mediated invasion and metastasis and induce T-cells. ACS Appl Mater Interfaces. 2019;11(8):7850–7861. doi:10.1021/acsami.8b22309
   PubMed Web of Science ®Google Scholar
• Liu Z, Ji P, Liu H, et al. FNIII14 peptide-enriched membrane nanocarrier to disrupt stromal barriers through reversing CAFs for augmenting drug penetration in tumors. Nano Lett. 2023; 23(21):9963–71.
   PubMed Web of Science ®Google Scholar
• Ni C, Lou X, Yao X, et al. ZIP1(+) fibroblasts protect lung cancer against chemotherapy via connexin-43 mediated intercellular Zn(2+) transfer. Nat Commun. 2022;13(1):5919. doi:10.1038/s41467-022-33521-4
   PubMed Web of Science ®Google Scholar
• Ford K, Hanley CJ, Mellone M, et al. NOX4 inhibition potentiates immunotherapy by overcoming cancer-associated fibroblast-mediated CD8 T-cell exclusion from tumors. Cancer Res. 2020;80(9):1846–1860. doi:10.1158/0008-5472.CAN-19-3158
   PubMed Web of Science ®Google Scholar
• Huang H, Wang Z, Zhang Y, et al. Mesothelial cell-derived antigen-presenting cancer-associated fibroblasts induce expansion of regulatory T cells in pancreatic cancer. Cancer Cell. 2022;40(6):656–673.e7. doi:10.1016/j.ccell.2022.04.011
   PubMed Web of Science ®Google Scholar
• Correa S, Grosskopf AK, Lopez Hernandez H, et al. Translational applications of hydrogels. Chem Rev. 2021;121(18):11385–11457. doi:10.1021/acs.chemrev.0c01177
   PubMed Web of Science ®Google Scholar
• Zeng Z, Zhang C, Li J, et al. Activatable polymer nanoenzymes for photodynamic immunometabolic cancer therapy. Adv Mater. 2021;33(4):e2007247. doi:10.1002/adma.202007247
   PubMed Web of Science ®Google Scholar
• Wang X, Ihara S, Li X, et al. Rod-scale design strategies for immune-targeted delivery system toward cancer immunotherapy. ACS Nano. 2019;13(7):7705–7715. doi:10.1021/acsnano.9b01271
   PubMed Web of Science ®Google Scholar
• Yang Y, Guo J, Huang L. Tackling TAMs for cancer immunotherapy: it’s nano time. Trends Pharmacol Sci. 2020;41(10):701–714. doi:10.1016/j.tips.2020.08.003
   PubMed Web of Science ®Google Scholar